(Sharecast News) - TheraCryf said on Monday that it has successfully manufactured clinical-grade material for its lead Ox-1 receptor antagonist, marking a key step towards initiating human trials.
The AIM-traded group said 2.57 kilograms of drug substance had been produced to Good Manufacturing Practice standards, making it suitable for use in...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE